DE:5664803.32, +0.16, +5.1%) the Hamburg, Germany, drug developer, the companies said. Evotec will pay stock valued at $4.75 a share, or $151.8 million, the companies said in a statement. Renovis closed at $3.32 on Tuesday, indicating Evotec is paying a 43% premium. Both boards have approved the deal. Before it closes, Evotec will seek to list its American depositary shares on the Nasdaq Global Market. Subject to a vote of Renovis holders and other conditions, the companies hope to close the deal in the first quarter. Cowen & Co. advised Renovis while Lehman Brothers advised Evotec. End of Story
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM